Abstract
Simple SummaryCholangiocarcinoma (CCA) is an epithelial malignancy with a dismal prognosis due to rapid tumoral spread and poor therapeutic options. Innovative therapies, such as immune-modulating drugs, are urgently needed. Here, we assessed the quantity and clinical implications of immune cells expressing the T cell immune response cDNA 7 receptor (TIRC7) in a cohort of 135 CCA patients. We found that TIRC7+ immune cells are present both in the tumor epithelia and in the stroma in the majority of patients with particularly high intraepithelial levels in intrahepatic CCA. Distinct histomorphological tumor subtypes were exclusively associated with a TIRC7+ phenotype. By correlation analysis, we uncovered that a high level of intraepithelial TIRC7+ immune cells was associated with a favorable prognosis in intrahepatic CCA. Our results reveal a distinct subset of immune cells marked by TIRC7 to be present and prognostically relevant in CCA.Cholangiocarcinoma (CCA) is a heterogeneous malignancy with a dismal prognosis. Therapeutic options are largely limited to surgery and conventional chemotherapy offers limited benefit. As immunotherapy has proven highly effective in various cancer types, we have undertaken a quantitative immunohistopathological assessment of immune cells expressing the immunoinhibitory T cell immune response cDNA 7 receptor (TIRC7), an emerging immunoinhibitory receptor, in a cohort of 135 CCA patients. TIRC7+ immune cells were present in both the tumor epithelia and stroma in the majority of CCA cases with the highest levels found in intrahepatic CCA. While intraepithelial density of TIRC7+ immune cells was decreased compared to matched non-neoplastic bile ducts, stromal quantity was higher in the tumor samples. Tumors exhibiting signet ring cell or adenosquamous morphology were exclusively associated with an intraepithelial TIRC7+ phenotype. Survival analysis showed intraepithelial TIRC7+ immune cell density to be a highly significant favorable prognosticator in intrahepatic but not proximal or distal CCA. Furthermore, intraepithelial TIRC7+ immune cell density correlated with the number of intraepithelial CD8+ immune cells and with the total number of CD4+ immune cells. Our results suggest the presence and prognostic relevance of TIRC7+ immune cells in CCA and warrant further functional studies on its pharmacological modulation.
Highlights
Cholangiocarcinoma (CCA) represents a group of biologically heterogeneous malignant epithelial tumors arising either from the intrahepatic or extrahepaticbiliary tract, with eCCA being further classified by either proximal or distallocation [1,2]
The absolute number of T cell immune response cDNA 7 receptor (TIRC7)+ immune cells in the stromal compartment was significantly higher in tumoral tissue as compared to non-neoplastic bile ducts (Figure 2E, p < 0.05)
By correlating our results with immune cell infiltrate characteristics in the same cohort, we found that high intraepithelial TIRC7+ immune cell densities were paralleled by an increased number of both intraepithelial CD8+ cytotoxic and total number of CD4+ T cells
Summary
Cholangiocarcinoma (CCA) represents a group of biologically heterogeneous malignant epithelial tumors arising either from the intrahepatic (iCCA) or extrahepatic (eCCA)biliary tract, with eCCA being further classified by either proximal (pCCA) or distal (dCCA)location [1,2]. Cholangiocarcinoma (CCA) represents a group of biologically heterogeneous malignant epithelial tumors arising either from the intrahepatic (iCCA) or extrahepatic (eCCA). Biliary tract, with eCCA being further classified by either proximal (pCCA) or distal (dCCA). Location [1,2]. CCAs most often present as aggressive, therapy-resistant adenocarcinomas characterized by early distant metastasis preventing surgical management [1]. Though recent studies provide new information on the molecular features of CCA, prognosis is overall still dismal with a median survival of less than one year [3]. Most patients are not eligible for resection at the time of diagnosis as symptoms tend to first emerge late in the course of the disease [4]. Considering the recent successes in targeted cancer therapies, innovative approaches are warranted for CCA patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
